Atlas Trials

Phase IIb Study Evaluating Immunogenic Chemotherapy Combined With Ipilimumab and Nivolumab in Breast Cancer

Clinical trial NCT03409198 · COMPLETED

Trial details

NCT number
NCT03409198
Sponsor
Oslo University Hospital
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast CancerHormone Receptor Positive TumorMetastatic Breast Cancer
Start date
2018-01-21
Primary completion
2022-05-11
Enrollment
82

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.